Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJudges Scientific Regulatory News (JDG)

Share Price Information for Judges Scientific (JDG)

Share Price is delayed by 15 minutes
Get Live Data
4,450.00    -25.00 (-0.54%)
Bid:
4,300.00
Ask:
4,600.00
Spread: 300.00 (6.977%)
Market Cap: £306.39m
JDG Live PriceLast checked at - London Stock Exchange

Intraday Judges Scientific Share Chart

Half Year Trading Update

24 Jul 2025 07:00

RNS Number : 3201S
Judges Scientific PLC
24 July 2025
 

The information contained within this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. The information is disclosed in accordance with the Company's obligations under Article 17 of the UK MAR. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

24 July 2025

Judges Scientific plc

("Judges Scientific", "the Company" or "the Group")

Half Year Trading Update and Notice of Interim Results

Judges Scientific (AIM: JDG), the group focused on acquiring and developing companies in the scientific instrument sector, provides the following update regarding the Group's trading performance for the six-month period ended 30 June 2025.

Trading in the first half of the financial year was materially impacted by performance in the US. Trading will show progress versus H1 2024, primarily driven by the completion of a coring expedition in Japan. However, excluding Geotek, the recovery expected from the Group's businesses did not materialise, due in particular to reductions in US federal government research funding (a risk highlighted in our year-end results announcement in March 2025). In addition, there were several unrelated market and product-specific challenges at a handful of our businesses that impacted performance. Improvement actions are underway in respect of these issues.

Order intake 

Across the Group, Organic* order intake was up 4% when compared with H1 2024. Organic orders were up in all regions except North America (down 18%) and the UK (down 7%).

Order book

The Organic order book was 17.4 weeks (FY 2024: 19.2 weeks; H1 2024: 17.2 weeks) and the total order book was 18.1 weeks.

Revenue

Organic revenue in the first half was up 7% compared with H1 2024; this reflects the coring contract and progress in all regions except North America (down 20%).

Profits

Geotek's profitability has now recovered from a difficult 2024. The Organic businesses excluding the contribution from Geotek, declined by 7% compared with H1 2024 with EBIT contribution reducing by a third primarily due to the aforementioned challenges.

As a result, Adjusted earnings per share in the first half is expected to have progressed by approximately 15% for the period.

Outlook

Our business relies heavily on public spending and the environment remains difficult, particularly in the US. More broadly, our Executive Committee continues to work closely with all our Group businesses to encourage growth, innovation, and improvement, with a determined effort to drive recovery at those companies that are experiencing trading challenges.

As a result of these headwinds coupled with the aforementioned business specific issues, the Board now anticipates delivering Adjusted basic earnings per share of between 285p and 330p per ordinary share in FY25 which is below market expectations**.

The Group still maintains a healthy order book, and a solid financial position underpinned by good cash generation, which gives the Board confidence that the disappointing performance of the first half does not hamper the Group's continuing strategy and its ability to deliver durable returns for shareholders.

*References to "Organic" information in this update exclude any contribution from Luciol SA, Rockwash Limited and Teer Coatings Limited. 

** Current consensus market expectations for the year ended 31 December 2025 are Adjusted basic earnings per share of 367.2p.

Notice of Results

The Company intends to announce its interim results for the six months to 30 June 2025 on Thursday 18 September 2025.

The person responsible for arranging the release of this announcement on behalf of the Company is Brad Ormsby, CFO of the Company.

For further information please contact: 

 

Judges Scientific plc

David Cicurel, CEO

Brad Ormsby, CFO

Tel: +44 (0) 20 3829 6970

 

 

Shore Capital (Nominated Adviser & Joint Broker)

Stephane Auton

Harry Davies-Ball

Tel: +44 (0) 20 7408 4090

 

Panmure Liberum (Joint Broker)

Edward Mansfield

Nikhil Varghese

Tel : +44 (0) 20 3100 2222

 

 

Investec Bank plc (Joint Broker)

Virginia Bull

Carlton Nelson

Tel: +44 (0) 20 7597 4000

Alma (Financial Public Relations)

Sam Modlin

Rebecca Sanders-Hewett

Joe Pederzolli

Sarah Peters

Tel: +44 (0) 20 3405 0205

judges@almastrategic.com

 

Notes to editors:

Judges Scientific plc (AIM: JDG), is a group focused on acquiring and developing companies in the scientific instrument sector. The Group now consists of 25 businesses acquired since 2005.

The acquired companies are primarily UK-based with products sold worldwide to a diverse range of markets including: higher education institutions, scientific research facilities, manufacturers and regulatory authorities. The UK is a recognised centre of excellence for scientific instruments. The Group has received five Queen's Awards for innovation and export.

The Group's companies predominantly operate in global niche markets, with long term growth fundamentals and resilient margins.

Judges Scientific maintains a policy of selectively acquiring businesses that generate sustainable profits and cash. Shareholder returns are created through the reduction of debt, organic growth and dividends.

For further information, please visit www.judges.uk.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBIGDRGUDDGUX
Date   Source Headline
29th Sep 20142:49 pmRNSHolding(s) in Company
24th Sep 20147:00 amRNSHalf Yearly Report
16th Sep 20147:00 amRNSNotice of Results
10th Sep 20147:00 amRNSDirector/PDMR Shareholding
8th Aug 20142:29 pmRNSDirector/PDMR Shareholding
22nd Jul 20147:00 amRNSDirector/PDMR Shareholding
18th Jul 20143:14 pmRNSHolding(s) in Company
17th Jul 20147:00 amRNSTrading Statement
9th Jul 20145:24 pmRNSDirector/PDMR Shareholding
6th Jun 20143:52 pmRNSDirector/PDMR Shareholding
5th Jun 201412:03 pmRNSIssue of Equity
3rd Jun 20144:15 pmRNSDirector/PDMR Shareholding
23rd May 20143:20 pmRNSExercise of options
22nd May 20147:00 amRNSPayment of deferred consideration for Scientifica
19th May 20143:08 pmRNSExercise of options
12th May 20141:54 pmRNSDirector/PDMR Shareholding
24th Apr 20145:30 pmRNSExercise of Options
10th Apr 201412:01 pmRNSExercise of options
8th Apr 20146:15 pmRNSDirector/PDMR Shareholding
4th Apr 20142:28 pmRNSExercise of Options
28th Mar 20147:00 amRNSFinal Results
10th Mar 201410:00 amRNSNotice of Results
10th Mar 20148:51 amRNSDirector/PDMR Shareholding
7th Feb 20142:53 pmRNSDirector/PDMR Shareholding
24th Jan 20147:00 amRNSTrading Statement
22nd Jan 20142:01 pmRNSExercise of Options
13th Jan 20141:40 pmRNSHolding(s) in Company
10th Jan 20146:00 pmRNSHolding(s) in Company
9th Jan 20144:34 pmRNSDirector/PDMR Shareholding
13th Dec 201310:31 amRNSIssue of Equity
10th Dec 20138:39 amRNSDirector/PDMR Shareholding
4th Dec 20134:06 pmRNSIssue of Equity
26th Nov 20133:31 pmRNSDirector/PDMR Shareholding
20th Nov 20137:00 amRNSTrading Statement
7th Nov 20132:04 pmRNSDirector/PDMR Shareholding
25th Oct 20135:24 pmRNSHolding(s) in Company
25th Oct 20134:19 pmRNSDirector/PDMR Shareholding
21st Oct 20137:00 amRNSPlacing to raise GBP8.125 million
9th Oct 20131:25 pmRNSDirector/PDMR Shareholding
2nd Oct 20135:47 pmRNSHolding(s) in Company
26th Sep 20137:00 amRNSHalf Yearly Report
17th Sep 20134:17 pmRNSNotice of Results
9th Sep 20134:15 pmRNSDirector/PDMR Shareholding
13th Aug 201312:48 pmRNSHolding(s) in Company
6th Aug 20134:33 pmRNSDirector/PDMR Shareholding
18th Jul 20132:04 pmRNSDirector/PDMR Shareholding
18th Jul 20137:00 amRNSTrading Statement
15th Jul 20134:59 pmRNSExercise of Options
10th Jul 20131:27 pmRNSExercise of options
9th Jul 20137:00 amRNSDirector/PDMR Shareholding and Issue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.